Agilent Technologies (A) said Monday that its PD-L1 IHC 28-8 pharmDx kit was approved for two new companion diagnostic indications in the European Union.
The kit is now approved as a companion diagnostic test for malignant melanoma and non-small cell lung cancer, Agilent said.
The new approvals bring the kit's total approved indications in Europe to nine, the company said.
Price: 123.91, Change: -2.79, Percent Change: -2.20
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。